2025 Q3 -tulosraportti
81 päivää sitten
‧42 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
250
Myynti
Määrä
1 400
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 592 | - | - | ||
| 1 000 | - | - | ||
| 727 | - | - | ||
| 1 000 | - | - | ||
| 3 100 | - | - |
Ylin
0,184VWAP
Alin
0,176VaihtoMäärä
0,3 1 468 836
VWAP
Ylin
0,184Alin
0,176VaihtoMäärä
0,3 1 468 836
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11.2. · MuokattuCan someone confirm or debunk the following claim, which I have calculated (numbers obtained via AI, note) : See below for why I propose these numbers: 0.1786 vs. 6.70 constitutes 3751 % (37.5x). Does this mean that this stock might have an upside potential of over 40x (4000 %) , (kr 7.14) ? I'm trying to put things into perspective. If someone is kind enough to triple-check the numbers and can provide input on how one should value the company, it would be appreciated? We are not all economists here on the forum. I am not. What dilution are we talking about that has occurred since early 2023 before the IMMray termination. Yes, 22.6 million shares. How many shares exist today, yes, 672.7 million. We are talking about 3.35 % remaining, if I have entered the numbers correctly here, mind you. Okay, if I have calculated correctly on those kr 200, then that dilution amounts to SEK 6.70 (is that correct)? I have searched for numbers via AI, so take it with a pinch of salt. But AI claims that these previous 22.6 million shares match these SEK 200 historical share price. So, in theory, the stock today, without any progress, should have been worth SEK 6.7? But then PancreaSure is a better test than IMMray® PanCan-d. What is the stock actually worth then? Taking into account the 25 medical centers versus today's somewhat semi-unknown number of KOL's? And don't forget the California approval now. That's probably a bonus that PancreaSure is alone in regarding IMMray? Sorry, I know too little about this, hence the question marks. Can this even be true? Has pessimism and the exhausting emissions stolen over 6 kroner per share?
·11.2. · MuokattuI cannot comment on the valuation, it feels far too theoretical for me. But what you write about California is not correct. In August 2022, Jeff wrote that they received the same approval for IMMray, half a year before the test was scrapped. https://www.prnewswire.com/news-releases/immunovia-inc-issued-clinical-and-public-health-laboratory-license-from-california-dept-of-public-health-for-immray-pancan-d-test-301604178.html Whether the test is actually better, we don't know yet - IMMray failed after larger clinical studies, and no such studies have been done or started for Pancreasure yet. IMMray was very dependent on CA 19-9, but Pancreasure is too (sensitivity drops to <60% without CA 19-9, and they themselves comment in their study that more studies are needed to determine if it is clinically useful for that group.) That Pancreasure lacks borderline-case is good, but since they excluded all patients with inflammation from their studies, we don't know if they have simply classified borderline as negative, and then tried to improve results ten by excluding difficult samples. Much remains to be proven.·11.2.Thanks for the correction regarding California. I can't edit it out of the post, because it's too late. So my and your answer will stand for the correction of it.- ·11.2.What can we expect from Q4 in a few days? We should probably get to know the runway of available funds, meaning that the burn rate is somewhat adjusted? Maybe some other news but it's hard to know. Other news could just as well be released at any time really, if it weren't to buy themselves a few weeks of maturation of the work with these KOLs. Information probably won't come before the Q4 presentation. Does this mean there's little to tell, or that it's just natural to include certain matters about continued operations in the financial presentations?
·3 päivää sittenQ4 will not provide much more than how many tests they have managed to sell, and possibly new centers showing interest. The company will not gain momentum until Medicare is finalized and insurance companies start paying full price. I also hope they clarify that sales will be handled internally and not via partners. Information on how the sales organization will be established is also interesting, but I believe they are quite particular about the profile of people hired, and that it will be a driven sales force. All this boils down to an updated burn rate versus a timeline for reimbursements. That determines if, when, and how much money will be missing going forward. - ·9.2. · MuokattuHow many øre does it need to go up in price before the stock becomes normally-trading again? So what are people who want to exit the stock satisfied with? And will those sellers at 19 øre give up one day? What's new today, February 9th, actually? Just a bit of price recovery, better global outlook for the stock markets? Or has something new come out that hasn't been officially released to all channels?·10.2.Unfathomable that one sells now at such a low price, when the interesting quarterly reports are ahead of us. There is almost only a total failure that would lower the price further, but there is forward-looking information that indicates an upturn in the near future...·10.2. · MuokattuI largely agree with what you are saying. Still, one never knows one hundred percent with the sales stage. But the product looks very good, if only they can get good sales going. People are welcome to sell as low as they want for me. But why they don't try to maximize (set a selling price to get the best payment) and achieve some recovery (higher daily common trading volume, by not slowing down trading, with this heavy sell-off) is difficult to understand. Unless there is an intention to keep a thinly traded stock suppressed. It almost seems a bit manipulative, but who knows what these sellers are thinking?
- ·6.2. · Muokattu@Micketro (Krosen) Did you take dilution into account when you claimed: https://forum.placera.se/inlagg/622912f1-c039-4ad6-8541-6b7c5937c07f AI says that the number you came up with would have placed you in the top 10 before the dilution took effect 😉 Also, one should remember that some of us are behind our broker's name: (from AI) : Anonymity: If you hold your shares through a "Kapitalförsäkring" (KF) or certain "Investeringssparkonto" (ISK) via a broker like Avanza or Nordnet, your name is often hidden behind the broker's name (e.g., "Avanza Pension").·6.2. · MuokattuSeveral people on Placera have historically exposed themselves by name. Unnecessary. Of course, many stand behind a fund manager, but there are also many private individuals in the top 20 (ironically, no one from management or the board except Jeff)·6.2. · MuokattuThe 30-Day "Closed Period" Under Article 19(11) of MAR, insiders—technically called PDMRs (Persons Discharging Managerial Responsibilities)—are strictly prohibited from trading during: The 30 calendar days leading up to the publication of an interim (quarterly) report or a year-end report. The End Date: The ban only lifts once the report is made public. One day, someone on the board will probably use insider trading to boost the share price? It is at least very normal for something to be owned on the insider side. The question is probably just timing and how they will present this in a lawful manner.
- ·5.2. · MuokattuI have a somewhat uneasy feeling that someone is coming in the days before Q4 and vacuuming up cheap shares 🫣 It's exactly what we need for a share price recovery, but this leaves a bit of a bad taste in the mouth to think that the share is so cheap when one doesn't get the joy of being able to buy so cheaply oneself. Many of us are stuck with what we bought previously. Then we'll see what is said at Q4, 24. February. Whether there will be light in this tunnel, or if it continues in a similar way. I believe that the management is working well, without having much reportable to give, before there is something reportable to give. At least it's a management that doesn't hype the stock with filler announcements in this company.·6.2. · MuokattuWhat is quite certain now is that the leader will not reveal anything new before Q4. He has said so himself. The exception is if an extraordinary general meeting is needed. Such as with what led to the now cancelled reverse split. Because there is also little time left until February 24.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
81 päivää sitten
‧42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11.2. · MuokattuCan someone confirm or debunk the following claim, which I have calculated (numbers obtained via AI, note) : See below for why I propose these numbers: 0.1786 vs. 6.70 constitutes 3751 % (37.5x). Does this mean that this stock might have an upside potential of over 40x (4000 %) , (kr 7.14) ? I'm trying to put things into perspective. If someone is kind enough to triple-check the numbers and can provide input on how one should value the company, it would be appreciated? We are not all economists here on the forum. I am not. What dilution are we talking about that has occurred since early 2023 before the IMMray termination. Yes, 22.6 million shares. How many shares exist today, yes, 672.7 million. We are talking about 3.35 % remaining, if I have entered the numbers correctly here, mind you. Okay, if I have calculated correctly on those kr 200, then that dilution amounts to SEK 6.70 (is that correct)? I have searched for numbers via AI, so take it with a pinch of salt. But AI claims that these previous 22.6 million shares match these SEK 200 historical share price. So, in theory, the stock today, without any progress, should have been worth SEK 6.7? But then PancreaSure is a better test than IMMray® PanCan-d. What is the stock actually worth then? Taking into account the 25 medical centers versus today's somewhat semi-unknown number of KOL's? And don't forget the California approval now. That's probably a bonus that PancreaSure is alone in regarding IMMray? Sorry, I know too little about this, hence the question marks. Can this even be true? Has pessimism and the exhausting emissions stolen over 6 kroner per share?·11.2. · MuokattuI cannot comment on the valuation, it feels far too theoretical for me. But what you write about California is not correct. In August 2022, Jeff wrote that they received the same approval for IMMray, half a year before the test was scrapped. https://www.prnewswire.com/news-releases/immunovia-inc-issued-clinical-and-public-health-laboratory-license-from-california-dept-of-public-health-for-immray-pancan-d-test-301604178.html Whether the test is actually better, we don't know yet - IMMray failed after larger clinical studies, and no such studies have been done or started for Pancreasure yet. IMMray was very dependent on CA 19-9, but Pancreasure is too (sensitivity drops to <60% without CA 19-9, and they themselves comment in their study that more studies are needed to determine if it is clinically useful for that group.) That Pancreasure lacks borderline-case is good, but since they excluded all patients with inflammation from their studies, we don't know if they have simply classified borderline as negative, and then tried to improve results ten by excluding difficult samples. Much remains to be proven.·11.2.Thanks for the correction regarding California. I can't edit it out of the post, because it's too late. So my and your answer will stand for the correction of it.
- ·11.2.What can we expect from Q4 in a few days? We should probably get to know the runway of available funds, meaning that the burn rate is somewhat adjusted? Maybe some other news but it's hard to know. Other news could just as well be released at any time really, if it weren't to buy themselves a few weeks of maturation of the work with these KOLs. Information probably won't come before the Q4 presentation. Does this mean there's little to tell, or that it's just natural to include certain matters about continued operations in the financial presentations?·3 päivää sittenQ4 will not provide much more than how many tests they have managed to sell, and possibly new centers showing interest. The company will not gain momentum until Medicare is finalized and insurance companies start paying full price. I also hope they clarify that sales will be handled internally and not via partners. Information on how the sales organization will be established is also interesting, but I believe they are quite particular about the profile of people hired, and that it will be a driven sales force. All this boils down to an updated burn rate versus a timeline for reimbursements. That determines if, when, and how much money will be missing going forward.
- ·9.2. · MuokattuHow many øre does it need to go up in price before the stock becomes normally-trading again? So what are people who want to exit the stock satisfied with? And will those sellers at 19 øre give up one day? What's new today, February 9th, actually? Just a bit of price recovery, better global outlook for the stock markets? Or has something new come out that hasn't been officially released to all channels?·10.2.Unfathomable that one sells now at such a low price, when the interesting quarterly reports are ahead of us. There is almost only a total failure that would lower the price further, but there is forward-looking information that indicates an upturn in the near future...·10.2. · MuokattuI largely agree with what you are saying. Still, one never knows one hundred percent with the sales stage. But the product looks very good, if only they can get good sales going. People are welcome to sell as low as they want for me. But why they don't try to maximize (set a selling price to get the best payment) and achieve some recovery (higher daily common trading volume, by not slowing down trading, with this heavy sell-off) is difficult to understand. Unless there is an intention to keep a thinly traded stock suppressed. It almost seems a bit manipulative, but who knows what these sellers are thinking?
- ·6.2. · Muokattu@Micketro (Krosen) Did you take dilution into account when you claimed: https://forum.placera.se/inlagg/622912f1-c039-4ad6-8541-6b7c5937c07f AI says that the number you came up with would have placed you in the top 10 before the dilution took effect 😉 Also, one should remember that some of us are behind our broker's name: (from AI) : Anonymity: If you hold your shares through a "Kapitalförsäkring" (KF) or certain "Investeringssparkonto" (ISK) via a broker like Avanza or Nordnet, your name is often hidden behind the broker's name (e.g., "Avanza Pension").·6.2. · MuokattuSeveral people on Placera have historically exposed themselves by name. Unnecessary. Of course, many stand behind a fund manager, but there are also many private individuals in the top 20 (ironically, no one from management or the board except Jeff)·6.2. · MuokattuThe 30-Day "Closed Period" Under Article 19(11) of MAR, insiders—technically called PDMRs (Persons Discharging Managerial Responsibilities)—are strictly prohibited from trading during: The 30 calendar days leading up to the publication of an interim (quarterly) report or a year-end report. The End Date: The ban only lifts once the report is made public. One day, someone on the board will probably use insider trading to boost the share price? It is at least very normal for something to be owned on the insider side. The question is probably just timing and how they will present this in a lawful manner.
- ·5.2. · MuokattuI have a somewhat uneasy feeling that someone is coming in the days before Q4 and vacuuming up cheap shares 🫣 It's exactly what we need for a share price recovery, but this leaves a bit of a bad taste in the mouth to think that the share is so cheap when one doesn't get the joy of being able to buy so cheaply oneself. Many of us are stuck with what we bought previously. Then we'll see what is said at Q4, 24. February. Whether there will be light in this tunnel, or if it continues in a similar way. I believe that the management is working well, without having much reportable to give, before there is something reportable to give. At least it's a management that doesn't hype the stock with filler announcements in this company.·6.2. · MuokattuWhat is quite certain now is that the leader will not reveal anything new before Q4. He has said so himself. The exception is if an extraordinary general meeting is needed. Such as with what led to the now cancelled reverse split. Because there is also little time left until February 24.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
250
Myynti
Määrä
1 400
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 592 | - | - | ||
| 1 000 | - | - | ||
| 727 | - | - | ||
| 1 000 | - | - | ||
| 3 100 | - | - |
Ylin
0,184VWAP
Alin
0,176VaihtoMäärä
0,3 1 468 836
VWAP
Ylin
0,184Alin
0,176VaihtoMäärä
0,3 1 468 836
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
2025 Q3 -tulosraportti
81 päivää sitten
‧42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 27.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11.2. · MuokattuCan someone confirm or debunk the following claim, which I have calculated (numbers obtained via AI, note) : See below for why I propose these numbers: 0.1786 vs. 6.70 constitutes 3751 % (37.5x). Does this mean that this stock might have an upside potential of over 40x (4000 %) , (kr 7.14) ? I'm trying to put things into perspective. If someone is kind enough to triple-check the numbers and can provide input on how one should value the company, it would be appreciated? We are not all economists here on the forum. I am not. What dilution are we talking about that has occurred since early 2023 before the IMMray termination. Yes, 22.6 million shares. How many shares exist today, yes, 672.7 million. We are talking about 3.35 % remaining, if I have entered the numbers correctly here, mind you. Okay, if I have calculated correctly on those kr 200, then that dilution amounts to SEK 6.70 (is that correct)? I have searched for numbers via AI, so take it with a pinch of salt. But AI claims that these previous 22.6 million shares match these SEK 200 historical share price. So, in theory, the stock today, without any progress, should have been worth SEK 6.7? But then PancreaSure is a better test than IMMray® PanCan-d. What is the stock actually worth then? Taking into account the 25 medical centers versus today's somewhat semi-unknown number of KOL's? And don't forget the California approval now. That's probably a bonus that PancreaSure is alone in regarding IMMray? Sorry, I know too little about this, hence the question marks. Can this even be true? Has pessimism and the exhausting emissions stolen over 6 kroner per share?·11.2. · MuokattuI cannot comment on the valuation, it feels far too theoretical for me. But what you write about California is not correct. In August 2022, Jeff wrote that they received the same approval for IMMray, half a year before the test was scrapped. https://www.prnewswire.com/news-releases/immunovia-inc-issued-clinical-and-public-health-laboratory-license-from-california-dept-of-public-health-for-immray-pancan-d-test-301604178.html Whether the test is actually better, we don't know yet - IMMray failed after larger clinical studies, and no such studies have been done or started for Pancreasure yet. IMMray was very dependent on CA 19-9, but Pancreasure is too (sensitivity drops to <60% without CA 19-9, and they themselves comment in their study that more studies are needed to determine if it is clinically useful for that group.) That Pancreasure lacks borderline-case is good, but since they excluded all patients with inflammation from their studies, we don't know if they have simply classified borderline as negative, and then tried to improve results ten by excluding difficult samples. Much remains to be proven.·11.2.Thanks for the correction regarding California. I can't edit it out of the post, because it's too late. So my and your answer will stand for the correction of it.
- ·11.2.What can we expect from Q4 in a few days? We should probably get to know the runway of available funds, meaning that the burn rate is somewhat adjusted? Maybe some other news but it's hard to know. Other news could just as well be released at any time really, if it weren't to buy themselves a few weeks of maturation of the work with these KOLs. Information probably won't come before the Q4 presentation. Does this mean there's little to tell, or that it's just natural to include certain matters about continued operations in the financial presentations?·3 päivää sittenQ4 will not provide much more than how many tests they have managed to sell, and possibly new centers showing interest. The company will not gain momentum until Medicare is finalized and insurance companies start paying full price. I also hope they clarify that sales will be handled internally and not via partners. Information on how the sales organization will be established is also interesting, but I believe they are quite particular about the profile of people hired, and that it will be a driven sales force. All this boils down to an updated burn rate versus a timeline for reimbursements. That determines if, when, and how much money will be missing going forward.
- ·9.2. · MuokattuHow many øre does it need to go up in price before the stock becomes normally-trading again? So what are people who want to exit the stock satisfied with? And will those sellers at 19 øre give up one day? What's new today, February 9th, actually? Just a bit of price recovery, better global outlook for the stock markets? Or has something new come out that hasn't been officially released to all channels?·10.2.Unfathomable that one sells now at such a low price, when the interesting quarterly reports are ahead of us. There is almost only a total failure that would lower the price further, but there is forward-looking information that indicates an upturn in the near future...·10.2. · MuokattuI largely agree with what you are saying. Still, one never knows one hundred percent with the sales stage. But the product looks very good, if only they can get good sales going. People are welcome to sell as low as they want for me. But why they don't try to maximize (set a selling price to get the best payment) and achieve some recovery (higher daily common trading volume, by not slowing down trading, with this heavy sell-off) is difficult to understand. Unless there is an intention to keep a thinly traded stock suppressed. It almost seems a bit manipulative, but who knows what these sellers are thinking?
- ·6.2. · Muokattu@Micketro (Krosen) Did you take dilution into account when you claimed: https://forum.placera.se/inlagg/622912f1-c039-4ad6-8541-6b7c5937c07f AI says that the number you came up with would have placed you in the top 10 before the dilution took effect 😉 Also, one should remember that some of us are behind our broker's name: (from AI) : Anonymity: If you hold your shares through a "Kapitalförsäkring" (KF) or certain "Investeringssparkonto" (ISK) via a broker like Avanza or Nordnet, your name is often hidden behind the broker's name (e.g., "Avanza Pension").·6.2. · MuokattuSeveral people on Placera have historically exposed themselves by name. Unnecessary. Of course, many stand behind a fund manager, but there are also many private individuals in the top 20 (ironically, no one from management or the board except Jeff)·6.2. · MuokattuThe 30-Day "Closed Period" Under Article 19(11) of MAR, insiders—technically called PDMRs (Persons Discharging Managerial Responsibilities)—are strictly prohibited from trading during: The 30 calendar days leading up to the publication of an interim (quarterly) report or a year-end report. The End Date: The ban only lifts once the report is made public. One day, someone on the board will probably use insider trading to boost the share price? It is at least very normal for something to be owned on the insider side. The question is probably just timing and how they will present this in a lawful manner.
- ·5.2. · MuokattuI have a somewhat uneasy feeling that someone is coming in the days before Q4 and vacuuming up cheap shares 🫣 It's exactly what we need for a share price recovery, but this leaves a bit of a bad taste in the mouth to think that the share is so cheap when one doesn't get the joy of being able to buy so cheaply oneself. Many of us are stuck with what we bought previously. Then we'll see what is said at Q4, 24. February. Whether there will be light in this tunnel, or if it continues in a similar way. I believe that the management is working well, without having much reportable to give, before there is something reportable to give. At least it's a management that doesn't hype the stock with filler announcements in this company.·6.2. · MuokattuWhat is quite certain now is that the leader will not reveal anything new before Q4. He has said so himself. The exception is if an extraordinary general meeting is needed. Such as with what led to the now cancelled reverse split. Because there is also little time left until February 24.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
250
Myynti
Määrä
1 400
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 592 | - | - | ||
| 1 000 | - | - | ||
| 727 | - | - | ||
| 1 000 | - | - | ||
| 3 100 | - | - |
Ylin
0,184VWAP
Alin
0,176VaihtoMäärä
0,3 1 468 836
VWAP
Ylin
0,184Alin
0,176VaihtoMäärä
0,3 1 468 836
Välittäjätilasto
Dataa ei löytynyt